Lv2
200 积分 2024-11-04 加入
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
8天前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
18天前
已完结
Incidence of antibody–drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis
18天前
已完结
The evolving landscape of metastatic HER2-positive, hormone receptor-positive breast cancer
18天前
已完结
Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects
18天前
已完结
Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar
18天前
已完结
Clinical Management, Monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
18天前
已完结
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
18天前
已完结
Optimizing treatment for HER2-positive HR-positive breast cancer
18天前
已完结
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
18天前
已完结
皖公网安备34019202002308
